NOXON LTD
General Data
Reg Number
516731973
Sector
Biomed
Established
2023
No. of Employees
8
Stage
R&D
Additional Funding
1
Description
Pulmonary fibrosis is a feature of several diseases involving lung parenchyma or the airways
Technology
Noxon is developing a novel drug for oral treatment of fibrotic lung diseases.
Targeted Customers
IPF market.
Management personnel
Firas Younis - CEO
Winning details
Route name
Winning year
Technological Incubators 2020
Technological Incubators 2020
2024